Society Testimony

Testimony to FDA on Flibanserin

June 04, 2015

Endocrine Society Testimony to the Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee

"The Society is encouraged by the FDA’s focus on drug development for FSD, but cautions that most existing medications should be limited in their use due to limited efficacy data from studies published to date. However, studies with flibanserin show an effect size similar or greater than studies for drugs for male sexual dysfunction. Thus, similar levels of evidence should be used to approve drugs for women as for men. "

arrowRead the Full Testimony

Last Updated:

Policy Communications

Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Journals

The Best of Endocrine Society Journals 2020

Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.

Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!